Discover personalized clinical trial options designed to support your journey, safely, confidentially, and at no cost.
Takes less than 2 minutes • 100% confidential
Obesity is a significant health condition affecting 31% of UAE adults. Research is ongoing to improv…
Condition-specific symptoms, Consult a specialist, Early diagnosis advised and more.
Genetic and hereditary factors; Environmental exposures.
Medical Management, Lifestyle Modifications and more.
Symptoms
Common Symptoms
Quality of Life Impact
Managing this condition with proper medical care can significantly improve quality of life. A coordinated care team approach is recommended.
With the right care and support, most people live full, active lives.
Causes & Risk Factors
Health Insights
Active Global Trials
21+
Across all phases
Symptom Frequency
78%
Patients report primary symptom
Trial Improvement Rate
68%
Report improvement within 3 months
Avg. Trial Duration
14 mo
Median length of participation
Symptom Frequency Among Patients
Treatment
Evidence-based medications tailored to disease severity and patient profile.
Diet, exercise, and behavioral interventions as appropriate.
Regular follow-up with a specialist in this condition.
Clinical Trials
Novo Nordisk UAE
Evaluating the efficacy and safety of semaglutide 2.4mg weekly for weight management in UAE adult population.
NCT05712398
Daily Life
You are not alone. Millions of people navigate this condition every day, and with the right support system and treatments, a meaningful life is absolutely within reach.
Community Support
Connect with thousands of patients and caregivers
Digital Tools
Track symptoms and share insights with your care team
Specialist Network
Access to leading neurologists and researchers
Education Hub
Evidence-based resources tailored to your journey
Why Join a Trial
Try innovative therapies before they're widely available, some with breakthrough potential.
Receive close monitoring and support from leading specialists throughout the trial.
Study-related care, tests, and the investigational treatment are provided at no charge.
Research Pipeline
Current pipeline overview for Obesity
Pipeline data is indicative. Source: ClinicalTrials.gov & WHO ICTRP.
News
Tirzepatide Shows 22% Weight Loss in Landmark SURMOUNT-5 Trial
Eli Lilly's tirzepatide demonstrated superior weight loss compared to semaglutide in the head-to-head SURMOUNT-5 trial, with a mean reduction of 22.8% body weight.
NIH · Mar 10, 2025
FAQ
Resources
